Active Pharmaceutical Ingredients Market Is Set To Be worth 205.51 Billion USD by 2020

The report "Active Pharmaceutical Ingredients Market by type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech), Type of Manufacturer (Captive, Merchant), Therapy (Oncology, diabetes, Orthopedic, CNS, Nephrology, Ophthalmology) - Global Forecast to 2020", The global Active Pharmaceutical Ingredients market is expected to reach USD 205.51 Billion by 2020 from USD 150 Billion in 2015, at a CAGR of 6.5% during the forecast period.

Browse 121 market data tables and 56 figures spread through 206 pages and in-depth TOC on “Active Pharmaceutical Ingredients Market”
Early buyers will receive 10% customization on report.

The APIs market is witnessing tremendous growth across the globe due to the factors such as increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets for biosimilars and increasing scope for Highly potent active ingredients. Key players in the market are focusing new product launches, partnerships and collaborations, acquisitions, and expansion to grow in the market.

Talk to Our Research Analysts for More Info@

On the basis of type, the APIs market is segmented into Innovative and generic APIs. The generic APIs segment offers lucrative growth opportunities and represents a new revenue pocket for the APIs market. There is a tremendous growth in the adoption of generic equivalents of the innovative APIs products. The high growth of the generic APIs segment is attributed to the impending patent cliff of major blockbuster drugs, drying up product pipelines for new innovative products, increasing healthcare expenses and governmental emphasis on the greater use of generics.

On the basis of type of manufacturer, the APIs market is segmented into Captive manufacturer and Merchant manufacture. The merchant manufacturer segment is poised to grow at the highest CAGR during the forecast period owing to the growing trend of large pharmaceutical companies outsourcing API production to CMOs and low cost manufacturing capabilities of players in Asia Pacific.

North America dominates the APIs market. Europe represents the second-largest market; however, it is growing at a lower rate mainly due to the competition from U.S. and pharmerging markets of Asia. The Asian market is expected to register the highest CAGR owing to factors such as low labor and manufacturing costs, increasing disposable income, increasing prevalence of lifestyle and age related diseases and governmental emphasis on healthcare reforms.

Get The Sample Copy Of This Report:

Factors such as the increasing incidence of life style and age related diseases, Increasing prevalence of cancer across the world, Technological advancements in the APIs Manufacturing, Emerging markets for biosimilars and increasing scope for Highly potent active ingredients are driving market growth. On the other hand, stringent regulatory requirements and global economic recession may restrict market growth.

Key market players Teva Pharmaceuticals limited (Israel), Sun Pharmaceuticals Industries Limited (India), Dr. Reddy’s Laboratories Ltd. (India), Aurobindo (India), Novartis International AG (Switzerland), Boehringer Ingelheim (Germany), Albemarle Corporation (U.S.), Sigma Aldrich (U.S.), Mylan (U.K.), Allergan plc. (Ireland).

Browse Related Reports:
Injectable Drug Delivery Market
by Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, Immunization), Administration (Skin, Musculoskeletal), End User (Hospital, Home Care Setting) - Global Forecast to 2020.

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) & Application (Oncology, Blood Disorders) - Global Forecast to 2020.

About MarketsandMarkets:
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @

Mr. Rohan
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Visit MarketsandMarkets Blog @
Connect with us on LinkedIn @